{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-012619","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.714506+00:00","generated_at":"2026-06-25T23:33:31.006994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M","bullets":["First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.","Net loss $28.1M ($0.21 per share) vs $33.2M ($0.34 per share) YoY improvement.","Cash & investments $89.7M at March 31, 2022, down from $116.7M at Dec 31, 2021.","FDA to convene advisory committee for XPHOZAH (phosphate binder) for hyperphosphatemia in CKD on dialysis.","Amended Kyowa Kirin deal: up to $40M additional milestones; royalty rate reduced from high teens to low double digits."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-012619","json":"https://secwatch.observer/filing/0001628280-22-012619.json","markdown":"https://secwatch.observer/filing/0001628280-22-012619.md","text":"https://secwatch.observer/filing/0001628280-22-012619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/0001628280-22-012619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/ardx-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:33:31.006994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}